ASSESSMENT OBJECTIVE: Despite the review on the use of aromatase inhibitors be applied in some studies concerning short time, Professor. JP Hammerstein the University of Berlin, discoverer and developer of one of the substances most commonly used as aromatase inhibitors , yet in the 50/60 the last century , raised this possibility , adding a molecule of Cl in cyclohexane : 3'H cyclopropyl (1,2) pregna -1 ,4,6- triene 3,20 - dione ,6 -chloro- 1 ,2 -beta -beta -dihydro- 17-hydroxy- although the primary objective was not this, eventually emptying into a new therapeutic approach in patients with short stature, although there are other aromatase inhibitors, in an attempt to prevent rapid bone age advancement, dependent on estrogen production, even in males . More recently , in a study conducted by researchers including Tanaka T, Satoh M, Hibi Eu., the conclusion of the Japanese group was specific regarding the importance of aromatase inhibitors applied in short stature in endocrinology, neuroendocrinology, physiology, as well as pediatric (endocrine subspecialty) endocrinology.
IMPORTANCE: Researchers including Tanaka T, Satoh M, Hibi Eu., Japanese as was explained to the patients a chance to increase the final height in the treatment of gonadal suppression and the risk of delayed pubertal development, which will be later fired so natural and normal almost all children preferred to have higher than earlier pubertal development which would lead to a lower final height, so they did not have much psychological difficulty longitudinal end time, as this detail is reversible after prolonged height treatment.
SOURCES: MEDLINE, a survey of the past 10 years, with the terms aromatase inhibitor, short stature and precocious puberty,
DATA SYNTHESIS: It has become evident that the bone age advancement depends on estrogen production and action of this hormone on the growth plate. In males, testosterone is converted to estradiol by the cytochrome P450 enzyme aromatase. The use of aromatase inhibitors has been shown to be effective in prolonging the growth in children with idiopathic short stature , constitutional delay of growth and puberty and even in children with growth hormone deficiency, in which the bone age advancement jeopardizes the results of hormone replacement therapy with growth hormone. There have been problems with adverse effects, and the results are encouraging in terms of effective increase in height, whenever the indication is appropriate.
CONCLUSIONS: Among the pharmacological treatments for short stature, aromatase inhibitors are indicated in cases where the bone age advancement may constitute an obstacle to a final height within the familial patterns of the patient (AU).
Dr. João Santos Caio Jr.
Endocrinologia – Neuroendocrinologista
CRM 20611
Dra. Henriqueta V. Caio
Endocrinologista – Medicina Interna
CRM 28930
Como saber mais:
1. O crescimento somático e maturação são influenciados por diversos fatores que atuam de forma independente ou em conjunto para modificar o potencial genético de um indivíduo...
http://hormoniocrescimentoadultos.blogspot.com.
2. O coeficiente de correlação para a altura do adulto é apenas 0,25 no nascimento, mas é de 0,80 por 2 anos de idade...
http://longevidadefutura.blogspot.com
3. As diferenças no crescimento e desenvolvimento também variam em função do sexo e origem étnica...
http://imcobesidade.blogspot.com
AUTORIZADO O USO DOS DIREITOS AUTORAIS COM CITAÇÃO
DOS AUTORES PROSPECTIVOS ET REFERÊNCIA BIBLIOGRÁFICA.
Referências Bibliográficas:
Caio Jr, João Santos, Dr.; Endocrinologista, Neuroendocrinologista, Caio,H.V., Dra. Endocrinologista, Medicina Interna – Van Der Häägen Brazil, São Paulo, Brasil; Brodie AM, Bancos PK, Inkster SE, Dowsett M, Coombes RC. Inibidores da aromatase e os cancros dependentes de hormonas. J. Steroid Biochem Mol Biol. 1.990 ; 37 (3): 327 – 333; Bulun SE, Zeitoun K, Takayama K, et al. Produção de estrogénio na endometriose e utilização de inibidores de aromatase para o tratamento da endometriose. Endocr Relat Câncer. 1.999 ; 6 (2): 293 – 301; Miller WR, Jackson J. O potencial terapêutico dos inibidores da aromatase. Expert Opin Investig Drugs. 2.003 ; 12 (3): 337 – 351; Dunkel L. O uso de inibidores da aromatase para aumentar a altura final. Mol Endocrinol celular. 2.006 ; 254 - 255:207-216; Plourde PV, Reiter EO, Jou HC, et al. Os membros do Estudo Ginecomastia AsraZeneca. A segurança ea eficácia do anastrozol no tratamento de ginecomastia puberal: um duplo-cego, randomizado, controlado por placebo. J Clin Endocrinol Metab. 2.004 ; 89 (9): 4428 – 4433; Smith EP, Boyd J, Frank GR, et al. Resistência estrogênio causada por uma mutação no gene receptor de estrogênio em um homem. N Engl J Med. de 1994 ; 331 (16): 1056 – 1061; Um Morishima, Grumbach M, Simpson E, Fisher C, Qin K. aromatase deficiência em irmãos masculinos e femininos causados por uma mutação nova e o papel fisiológico de estrogénios. J Clin Endocrinol Metab. 1.995 ; 80 (12): 3689 - 3698 ; Caixa R, Brough AJ, Cohen MN, Satoh PS. Aminoglutetimida (Elipten-Ciba) como um inibidor da esteroidogênese adrenal: mecanismo de ação e julgamento terapêutico. J Clin Endocrinol Metab. 1.967 ; 27 (9): 1239 – 1248; Thompson EA Jr, Siiteri PK. O envolvimento de placenta humana do citocromo P-450 microssomal em aromatização. J. Biol Chem. 1.974 ;249 (17): 5373 – 5378.
Contato: Fones: 55 (11) 2371-3337 - 5572-4848 ou 98197-4706 tim
Rua Estela, 515 - Bloco D - 12º andar - Conj. 121/122
Paraiso - São Paulo - SP - Cep 04011-002
e-mail: vanderhaagenbrasil@gmail.com
Site Van Der Haagen Brazil
www.vanderhaagenbrazil.com.br,
http://drcaiojr.site.med.br/
http://dracaio.site.med.br/
Video
Google Maps:
http://maps.google.com.br/maps/place?cid=5099901339000351730&q=Van+Der+Haagen+Brasil&hl=pt&sll=-23.578256,-46.645653&sspn=0.005074,0.009645&ie=UTF8&ll=-23.575591,-46.650481&spn=0,0&t=h&z=17
